Table 2.
Demographic and clinical characteristics of patients who received non-experimental ICI.
| Histology | BRAF alteration | BRAF class | Concurrent alterations | TMB | PD-L1 (%) | ICI line of therapy | ICI | Time on ICI (months) | Best RECIST response |
|---|---|---|---|---|---|---|---|---|---|
| Adeno | V600E | I | 5 | n/a | 2 | Nivolumab | 1.3* | NA | |
| Adeno | p.V600E | I | 6 | 0 | 2 | Nivolumab | 0.5 | PD | |
| Adeno | p.V600E | I | 10 | n/a | 1 | Ipilimumab and Nivolumab | 5.5 | PD | |
| Adeno | p.V600E | I | 5 | n/a | 2 | Nivolumab | 27.9 | SD | |
| Adeno | p.V600E | I | 10 | n/a | 2 | Nivolumab | 0.4 | PD | |
| Adeno | p.V600E | I | 7 | 99 | 3 | Atezolizumab | 1.4 | SD | |
| Adeno | p.V600E | I | 3 | n/a | 5 | Nivolumab | 1.4 | SD | |
| Adeno | V600E | I | 1 | 90 | 3 | Pembrolizumab | 11.3 | NA | |
| Adeno | p.V600E | I | 13 | n/a | 4 | Pembrolizumab | 1.4 | PD | |
| Adeno | p.V600E | I | 6 | n/a | 2 | Nivolumab | 0.6 | PD | |
| Adeno | p.V600E | I | 19 | 70 | 3 | Pembrolizumab | 28.2* | PR | |
| Adeno | V600E | I | 2 | 10 | 1 | Ipilimumab and Nivolumab | 0.5 | SD | |
| Adeno | V600E | I | 2 | 10 to 20 | 4 | Pembrolizumab | 11.5* | SD | |
| Adeno | p.G469A | II | 7 | 20 | 4 | Nivolumab | 1.8 | PD | |
| Adeno | p.T599dup | II | 14 | n/a | 3 | Nivolumab | 0.04 | NA | |
| Adeno | p.G469A | II | 10 | 10 | 3 | Nivolumab | 1.4 | PD | |
| Squamous Cell | p.G469A | II | 1 | 0 | 3 | Nivolumab | 40.1 | PR | |
| Adeno | SND1 (NM_014390) - BRAF (NM_004333) | II | 4 | n/a | 4 | Nivolumab | 0.5 | PD | |
| Adeno | BRAF (NM_004333) - MRPS33 (NM_053035)Rearrangement | II | 3 | n/a | 6 | nivolumab | 0.5 | NA | |
| Adeno | p.G469A | II | KRAS G13C | 9 | n/a | 2 | Nivolumab | 0.06 | NA |
| Adeno | AGAP3 (NM_031946) - BRAF (NM_004333) rearrangement | II | 3 | 0 | 4 | Nivolumab | 2.3 | PD | |
| Adeno | p.G + AD2:AF121464R | II | KRAS G12V and NF1 | 10 | 0 | 1 | Ipilimumab and Nivolumab | 3.9 | PD |
| Adeno | AGK (NM_018238) - BRAF (NM_004333) rearrangement | II | 0 | n/a | 3 | Nivolumab | 0.06 | NA | |
| Adeno | p.G464V | II | 6 | n/a | 2 | Nivolumab | 2.2 | PD | |
| Neuroendocrine Tumour | p.G469A | II | 19 | n/a | 2 | Ipilimumab and Nivolumab | 1.4 | PD | |
| Adeno | p.G469A | II | 5 | 0 | 3 | Nivolumab | 4.4 | SD | |
| Adeno | p.G464V | II | KRAS G13D | 8 | 80 | 1 | Pembrolizumab | 0.06 | NA |
| Adeno | p.K601E | II | 11 | 0 | 2 | Pembrolizumab (with chemotherapy) | 5.6 | CR | |
| Adeno | p.G469S | II | NF1 | 6 | n/a | 1 | Pembrolizumab | 6.0 | PR |
| Large Cell Neuroendocrine | G469A | II | 8 | 1 | 2 | Atezolizumab | 1.4 | PD | |
| Adeno | p.V600_K601delinsE | II | 3 | 99 | 1 | Pembrolizumab (with chemotherapy) | 4.2 | PR | |
| Adeno | p.G596R | III | NF1 | 22 | 0 | 2 | Nivolumab | 34.8 | PD |
| Adeno | p.G596R | III | 11 | n/a | 3 | Nivolumab | 0.8 | PD | |
| Adeno | p.G466E | III | 20 | n/a | 1 | Ipilimumab and Nivolumab | 1.9 | PD | |
| Adeno | p.D594G | III | 6 | 5 | 4 | Nivolumab | 0.9 | PD | |
| Adeno | p.D594N | III | 7 | 0 | 2 | Nivolumab | 0.04 | NA | |
| Adeno | p.G469A | III | 14 | 0 | 2 | Nivolumab | 0.9 | NA | |
| Adeno | p.V471F | III | NF1 | 29 | n/a | 3 | Nivolumab | 5.8 | SD |
| Adeno | p.G466A | III | 4 | 10 | 2 | Pembrolizumab | 18.4 | PR | |
| Adeno | p.G596V | III | KRAS G12V | 10 | 5 | 1 | Pembrolizumab | 9.2 | CR |
| Adeno | p.S467L | III | 33 | 0 | 4 | Nivolumab | 9.7 | SD | |
| Adeno | p.N581S | III | 11 | n/a | 3 | Nivolumab | 1.9 | PD | |
| Adeno | p.N581I | III | 2 | 0 | 4 | Nivolumab | 1.3 | PD | |
| Adeno | p.V168L | U | 100 | n/a | 3 | Nivolumab | 44.2 | PD | |
| Adeno | p.I572F | U | KRAS G12V | 21 | 0 | 2 | Nivolumab | 39.8* | PD |
| Adeno | p.K483E | U | 2 | 0 | 6 | Nivolumab | 5.6 | PD | |
| Adeno | p.M620I | U | 23 | 5 | 2 | Nivolumab | 41.2 | SD | |
| Adeno | splicing variant | U | 20 | n/a | 3 | Atezolizumab | 0.7 | NA | |
| Adeno | p.M117L | U | 8 | 60 | 1 | Ipilimumab and Nivolumab | 3.7 | SD | |
| Small Cell Cancer | p.D40Y | U | 17 | n/a | 2 | Nivolumab | 0.06 | NA | |
| Adeno | p.N412S | U | 39 | 0 | 7 | Nivolumab | 7.1 | SD | |
| Adeno | E695Q | U | 17 | 0 | 3 | Nivolumab | 18.9 | PR | |
| Squamous Cell | p.S616Y | U | 21 | 20 | 2 | Nivolumab | 41.8* | CR | |
| Adeno | p.T274A | U | KRAS G12D and NF1 | 16 | 100 | 2 | Nivolumab | 0.9 | PD |
| Adeno | p.R239L | U | KRAS G12C | 18 | 0 | 2 | Nivolumab | 35.7* | SD |
| Adeno | splicing variant p.X380_splice | U | KRAS G12C | 14 | 0 | 2 | Atezolizumab | 1.4 | PD |
| Adeno | p.R266T | U | 48 | 0 | 2 | Nivolumab | 2.6 | PD | |
| Adeno | A404Cfs*9 | U | EGFR exon 20 insertion | 4 | 0 | 2 | Nivolumab | 0.9 | PD |
| Squamous Cell | p.I556F | U | 12 | 0 | 2 | Atezolizumab | 1.4 | NA | |
| Small Cell Cancer | p.P152S | U | 9 | n/a | 2 | Ipilimumab and Nivolumab | 0.06 | NA | |
| Adeno | p.A404Cfs*9 | U | 18 | n/a | 3 | Nivolumab | 0.8 | PD | |
| Adeno | p.V487L | U | NF1 | 18 | 1 | 2 | Pembrolizumab | 2.1 | PD |
Adeno adenocarcinoma, CR complete response, ICI immune checkpoint inhibitor, NA not available/not evaluable, PD progressive disease, PR partial response, SD stable disease, TMB tumour mutation burden, U variant of unknown significance. *Treatment ongoing.